Evidence Hub

Molecular Docking Analysis of Coumarin and Indole Derivatives Targeting the MexB and GyrB in Multidrug-resistant Pseudomonas aeruginosa Clinical Isolates

H. al-Fatlawy

Journal of Pure and Applied Microbiology, 2026

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa has emerged as a significant clinical threat due to its high resistance to multiple antibiotic classes and the limited effectiveness of current therapeutic options. This study aimed to evaluate selected coumarin and indole derivatives targeting the MexB and GyrB proteins of MDR P. aeruginosa using an integrated in silico approach, supported by molecular characterization of clinical isolates. A total of 44 clinical P. aeruginosa isolates recovered from sputum, urine, wound swabs, and burn swabs were examined for antimicrobial susceptibility, revealing extensive drug resistance. Complete resistance (100%) was observed against amoxicillin-clavulanic acid (AMC), cefotaxime (CTX), and trimethoprim-sulfamethoxazole (SXT). Resistance rates were 97.7% for ticarcillin-clavulanic acid (TIM), 88.63% for amikacin (AK), 60% for imipenem (IMP) and meropenem (MEM), and 52.27% for ciprofloxacin (CIP) and levofloxacin (LEV). PCR analysis confirmed the presence of the GyrB and MexB genes in all isolates. Representative PCR-positive isolates were sequenced and verified by BLAST analysis. The nucleotide sequence of the GyrB gene has been deposited in the DDBJ under accession number LC919849, and the corresponding protein sequence was assigned GenBank accession number BHR60112.1. Molecular modeling and structural validation of the GyrB and MexB proteins were performed prior to molecular docking analysis. Novobiocin and PAβN were selected as…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free